TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26021713

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cells (BMMCs) implantation
Number of subjects: 89
Study: 26021959

Group type: EXPERIMENTAL
Intervention: Acupuncture group A (specific acupoints along the stomach meridian)
Number of subjects: 706

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 706

Group type: COMPARATOR
Intervention: Itopride
Number of subjects: 706
Study: 26021978

Group type: EXPERIMENTAL
Intervention: GDM (lean diabetics)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Obesity (obese non-diabetics)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (lean non-diabetic)
Number of subjects: 63
Study: 26022951

Group type: EXPERIMENTAL
Intervention: Smoke-free legislation
Number of subjects: 1651675

Group type: EXPERIMENTAL
Intervention: Lower RTI admissions
Number of subjects: 1651675

Group type: EXPERIMENTAL
Intervention: Upper RTI admissions
Number of subjects: 1651675
Study: 26023175

Group type: EXPERIMENTAL
Intervention: Persistent AF (PersAF)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Overall AF burden
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation episode frequency
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Heart failure (HF) interaction with AF burden
Number of subjects: 323

Group type: COMPARATOR
Intervention: Monitoring frequency and duration
Number of subjects: 323
Study: 26024112

Group type: EXPERIMENTAL
Intervention: Frisén grade assessment by lay readers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frisén grade assessment by PRC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid pressure association with Frisén grade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frisén grade and fundus feature association with perimetric mean deviation
Number of subjects: 0
Study: 26024473

Group type: EXPERIMENTAL
Intervention: Biomass fuel users (wood, straw, crop residues, or dung)
Number of subjects: 12782

Group type: COMPARATOR
Intervention: Clean fuel users (electricity, liquefied petroleum gas, natural gas, or biogas)
Number of subjects: 12782
Study: 26024531

Group type: EXPERIMENTAL
Intervention: MiCK drug-induced apoptosis assay (used by physicians)
Number of subjects: 30
Study: 26024661

Group type: EXPERIMENTAL
Intervention: Injectable artesunate
Number of subjects: 749

Group type: COMPARATOR
Intervention: Injectable quinine
Number of subjects: 749
Study: 26024688

Group type: EXPERIMENTAL
Intervention: H. pylori seropositive individuals
Number of subjects: 4765

Group type: COMPARATOR
Intervention: H. pylori seronegative individuals
Number of subjects: 4765
Study: 26025012

Group type: EXPERIMENTAL
Intervention: Wolfram Syndrome (WFS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Type 1 Diabetes (T1DM)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 19
Study: 26025572

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg od
Number of subjects: 777

Group type: COMPARATOR
Intervention: Ticagrelor 90 mg bid
Number of subjects: 777
Study: 26025807

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine administered at 0, 2, and 6 months
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ACWY-CRM vaccine administered concomitantly at 0 months
Number of subjects: 38
Study: 26025933

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BV) at 10 mg/kg every 2 weeks, Temozolomide (TMZ) at 200 mg/m² per day on days 1-5, Irinotecan (CPT-11) at 125 mg/m² or 340 mg/m² every 2 weeks depending on antiepileptic drugs.
Number of subjects: 41
Study: 26025965

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily and Everolimus 5 mg daily until disease progression, intolerable toxicity, investigator or patient decision.
Number of subjects: 35
Study: 26026216

Group type: EXPERIMENTAL
Intervention: Orthostatic hypotension (OH)
Number of subjects: 290
Study: 26026264

Group type: EXPERIMENTAL
Intervention: Intraoperative optical coherence tomography (OCT)
Number of subjects: 8
Study: 26026390

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 148
Study: 26026738

Group type: EXPERIMENTAL
Intervention: hu3S193 (20mg/m² intravenously weekly for 8 weeks, up to 3 cycles)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 31
Study: 26027940

Group type: EXPERIMENTAL
Intervention: Multiple-source, constant-current, eight-contact DBS system
Number of subjects: 40
Study: 26028255

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 14 days) in mismatch repair-deficient colorectal cancers
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 14 days) in mismatch repair-proficient colorectal cancers
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 14 days) in mismatch repair-deficient non-colorectal cancers
Number of subjects: 41

Group type: COMPARATOR
Intervention: Mismatch repair-proficient tumors
Number of subjects: 41
Study: 26028668

Group type: EXPERIMENTAL
Intervention: High mesothelin expression (defined as positivity in more than 25% of cells)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: High mesothelin expression
Number of subjects: 93
Study: 26028965

Group type: EXPERIMENTAL
Intervention: Anagrelide therapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Anagrelide therapy in JAK2-positive patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Anagrelide therapy in JAK2-negative patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall response rate using last observation carried forward
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Anagrelide therapy in JAK2-positive patients (last observation carried forward)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Anagrelide therapy in JAK2-negative patients (last observation carried forward)
Number of subjects: 46
Study: 26030086

Group type: EXPERIMENTAL
Intervention: Neuromuscular performance
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Motor performance (MP)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Body fat percentage (BF%)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Body fat percentage (BF%) with poorest MP
Number of subjects: 403

Group type: COMPARATOR
Intervention: Cardiorespiratory performance (CP)
Number of subjects: 403
Study: 26030696

Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS) on quantitative emphysema and airway imaging phenotypes
Number of subjects: 12031

Group type: COMPARATOR
Intervention: Previously reported COPD and spirometric loci
Number of subjects: 12031
Study: 26030709

Group type: EXPERIMENTAL
Intervention: Bilateral anterior nuclear stimulation with Medtronic Activa PC+S device
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Placement of AN electrodes using a novel trajectory
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Postoperative stimulation of the anterior nucleus
Number of subjects: 2
Study: 26031269

Group type: EXPERIMENTAL
Intervention: Pressurized irrigation
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Preincision gentamicin injection
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combined intervention groups (pressurized irrigation and gentamicin)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study: 26031410

Group type: EXPERIMENTAL
Intervention: PBPK modeling and classical population PK modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model-based approaches for drug development
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model-based predictions
Number of subjects: 0
Study: 26031893

Group type: EXPERIMENTAL
Intervention: iVATS (image-guided video-assisted thoracoscopic surgery)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: iVATS
Number of subjects: 25
Study: 26032537

Group type: EXPERIMENTAL
Intervention: Traditional immunosuppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emerging pathways and therapeutic agents
Number of subjects: 0
Study: 26032890

Group type: EXPERIMENTAL
Intervention: Resting state MEG-independent component analysis (ICA) technique
Number of subjects: 0
Study: 26033209

Group type: EXPERIMENTAL
Intervention: Facebook recruitment strategy
Number of subjects: 1023
Study: 26033282

Group type: EXPERIMENTAL
Intervention: CBD 300 mg/day given orally starting 7 days before transplantation until day 30
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CBD plus standard GVHD prophylaxis
Number of subjects: 48
Study: 26035252

Group type: EXPERIMENTAL
Intervention: Pulse photoplethysmographic amplitude (PPGA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ANS state (ANSS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ANS index (ANSSi)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pulse photoplethysmographic indices
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sympathovagal modulation directed to the heart
Number of subjects: 10
Study: 26036953

Group type: EXPERIMENTAL
Intervention: Eucapnic Voluntary Hyperventilation (EVH) testing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cardiopulmonary Exercise Test (CPET)
Number of subjects: 10
Study: 26037515

Group type: EXPERIMENTAL
Intervention: Surgery for acromegaly
Number of subjects: 23
Study: 26037794

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D) implant
Number of subjects: 4800
Study: 26038121

Group type: EXPERIMENTAL
Intervention: Gene expression profiling of CD19(+)CD5(+)-B-lymphocytes
Number of subjects: 216
Study: 26038521

Group type: EXPERIMENTAL
Intervention: Family history of stroke
Number of subjects: 4232

Group type: EXPERIMENTAL
Intervention: Parental history of stroke
Number of subjects: 4232
Study: 26038537

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D) in patients with GFR <60
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D) in patients with GFR ≥60
Number of subjects: 1820

Group type: COMPARATOR
Intervention: Non-left bundle-branch block patients
Number of subjects: 1820
Study: 26038709

Group type: EXPERIMENTAL
Intervention: Troponin T > 0.05 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 0
Study: 26040252

Group type: EXPERIMENTAL
Intervention: Mobile app follow-up care using QoR9, VAS, surgery-specific questions, and surgical site photos submitted daily for the first 2 weeks and weekly for the following 2 weeks.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mobile app follow-up care
Number of subjects: 72

Group type: COMPARATOR
Intervention: In-person follow-up care
Number of subjects: 72
Study: 26040491

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) preoperative, intraoperative, postoperative
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) preoperative, postoperative
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham control (preoperative and postoperative placement of needles without skin penetration)
Number of subjects: 54
Study: 26040622

Group type: EXPERIMENTAL
Intervention: Ixabepilone (6 mg/m² per day for 5 days every 21 days)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ixabepilone
Number of subjects: 41
Study: 26040640

Group type: EXPERIMENTAL
Intervention: Mathematical model of human metabolism
Number of subjects: 140

Group type: COMPARATOR
Intervention: DLW/DXA method
Number of subjects: 140
Study: 26040641

Group type: EXPERIMENTAL
Intervention: Dairy foods with inorganic phosphates
Number of subjects: 7895

Group type: EXPERIMENTAL
Intervention: Dairy foods without inorganic phosphates
Number of subjects: 7895

Group type: EXPERIMENTAL
Intervention: Cereals/grains with inorganic phosphates
Number of subjects: 7895

Group type: EXPERIMENTAL
Intervention: eGFR <30
Number of subjects: 7895

Group type: EXPERIMENTAL
Intervention: eGFR 30-44
Number of subjects: 7895

Group type: EXPERIMENTAL
Intervention: eGFR 45-60
Number of subjects: 7895

Group type: EXPERIMENTAL
Intervention: BMI <18.5
Number of subjects: 7895

Group type: EXPERIMENTAL
Intervention: BMI ≥35-39
Number of subjects: 7895

Group type: EXPERIMENTAL
Intervention: BMI ≥40
Number of subjects: 7895
Study: 26040709

Group type: EXPERIMENTAL
Intervention: Probabilistic Reversal Learning (PRL)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Serial Reaction Time (SRT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 53
Study: 26040806

Group type: EXPERIMENTAL
Intervention: In-stent neoatherosclerosis (NA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No NA
Number of subjects: 88
Study: 26041100

Group type: EXPERIMENTAL
Intervention: TEG parameters before stenting
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: ADP-induced platelet-fibrin clot strength (MA)
Number of subjects: 218
Study: 26041651

Group type: EXPERIMENTAL
Intervention: Premenarcheal DHEAS
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Premenarcheal SHBG
Number of subjects: 177

Group type: COMPARATOR
Intervention: Postmenarcheal DHEAS
Number of subjects: 177

Group type: COMPARATOR
Intervention: Postmenarcheal SHBG
Number of subjects: 177

Group type: COMPARATOR
Intervention: Estrogens, progesterone, androstenedione, testosterone (pre- or postmenarche)
Number of subjects: 177
Study: 26041675

Group type: EXPERIMENTAL
Intervention: Term milk
Number of subjects: 28

Group type: COMPARATOR
Intervention: Preterm milk
Number of subjects: 28
Study: 26041763

Group type: EXPERIMENTAL
Intervention: Aplidin 5 mg/m(2) days 1-15, 28-day cycle until disease progression or unacceptable toxicity
Number of subjects: 24
Study: 26042486

Group type: EXPERIMENTAL
Intervention: IV oseltamivir 2-3 mg/kg (age<1 year) or 2.5-3 mg/kg (max. 100 mg; age 1-12 years) by slow IV infusion twice daily for up to 6 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: IV oseltamivir
Number of subjects: 17
Study: 26043810

Group type: EXPERIMENTAL
Intervention: velaglucerase alfa 30-60U/kg by intravenous infusion every other week
Number of subjects: 24

Group type: COMPARATOR
Intervention: imiglucerase ERT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: velaglucerase alfa
Number of subjects: 24
Study: 26044314

Group type: EXPERIMENTAL
Intervention: IBD subjects (IBD-I and IBD-N)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Crohn's disease (CD) subjects
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: HPV presence
Number of subjects: 270

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 270
Study: 26044316

Group type: EXPERIMENTAL
Intervention: Magnetic sphincter augmentation device
Number of subjects: 100
Study: 26044317

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Daclatasvir (n = 15)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sofosbuvir and Ribavirin (n = 8)
Number of subjects: 23
Study: 26045135

Group type: EXPERIMENTAL
Intervention: Monocyte-derived hepatocyte-like (MH) cells
Number of subjects: 54

Group type: COMPARATOR
Intervention: RUCAM scoring system
Number of subjects: 54
Study: 26045305

Group type: EXPERIMENTAL
Intervention: Micra transcatheter pacing system
Number of subjects: 140
Study: 26046014

Group type: EXPERIMENTAL
Intervention: Multi-level, stepped behavioral intervention
Number of subjects: 527

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 527
Study: 26046067

Group type: EXPERIMENTAL
Intervention: Intratumoral injection of Clostridium novyi-NT spores
Number of subjects: 1
Study: 26046412

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN DBS)
Number of subjects: 10
Study: 26046448

Group type: EXPERIMENTAL
Intervention: Group III (CRS with nasal polyps and bronchial asthma)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group I (CRS without nasal polyps or bronchial asthma)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group II (CRS with nasal polyps but without bronchial asthma)
Number of subjects: 90
Study: 26047468

Group type: EXPERIMENTAL
Intervention: Abdominal Functional Electrical Stimulation (AFES) applied for 20-40 minutes per day, five times per week for four weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (ventilator dependent tetraplegic participants matched based on injury level, age, and sex)
Number of subjects: 10
Study: 26048034

Group type: EXPERIMENTAL
Intervention: Subgroup 3 (patients with at least one variant allowing lysosomal localization of mutant MAN2B1)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Subgroup 3
Number of subjects: 66

Group type: COMPARATOR
Intervention: Subgroup 2 and/or subgroup 1 (with no lysosomal localization of mutant MAN2B1)
Number of subjects: 66
Study: 26048203

Group type: EXPERIMENTAL
Intervention: E. coli HU2117 (pre-coated study catheters)
Number of subjects: 10
Study: 26048252

Group type: EXPERIMENTAL
Intervention: Primary sclerosing cholangitis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Inflammatory bowel disease
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 26048404

Group type: EXPERIMENTAL
Intervention: Never-smokers with COPD (FEV1/FVC<lower limits of normal)
Number of subjects: 5176

Group type: EXPERIMENTAL
Intervention: Never-smokers
Number of subjects: 5176

Group type: EXPERIMENTAL
Intervention: Ever-smokers
Number of subjects: 5176

Group type: EXPERIMENTAL
Intervention: Never-smokers and ever-smokers
Number of subjects: 5176
Study: 26048686

Group type: EXPERIMENTAL
Intervention: High caloric (428 kcal) (13)C-Sodium Octanoate breath test OFF dopaminergic medication
Number of subjects: 37

Group type: COMPARATOR
Intervention: 100 mg oral Levodopa/25 mg Benserazide
Number of subjects: 37
Study: 26048877

Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Hypercarbia
Number of subjects: 106
Study: 26048961

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 20
Study: 26049121

Group type: EXPERIMENTAL
Intervention: Intraperitoneal catumaxomab infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: In vitro catumaxomab stimulation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: In vitro experiments with ascites microenvironment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: In vitro experiments with EpCAM(+) tumour cells
Number of subjects: 6
Study: 26049148

Group type: EXPERIMENTAL
Intervention: MS clinical trial datasets
Number of subjects: 1589

Group type: EXPERIMENTAL
Intervention: ADNI dataset
Number of subjects: 1589
Study: 26049686

Group type: EXPERIMENTAL
Intervention: Panitumumab treatment in mCRC patients (exact dosage and duration not specified)
Number of subjects: 3196

Group type: EXPERIMENTAL
Intervention: Panitumumab treatment in mCRC patients with confirmed WT KRAS exon 2 status
Number of subjects: 3196

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 3196
Study: 26049781

Group type: EXPERIMENTAL
Intervention: 2 μg/mL TCI propofol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 3 μg/mL TCI propofol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 4 μg/mL TCI propofol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dysphagia Severity Score (DSS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Observer's Assessment of Alertness/Sedation (OAAS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Penetration and Aspiration Scale (PAS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: OAAS
Number of subjects: 80
Study: 26049896

Group type: EXPERIMENTAL
Intervention: Olipudase alfa (0.1 to 3.0 mg/kg, intravenously every 2 weeks for 26 weeks)
Number of subjects: 5
Study: 26050535

Group type: EXPERIMENTAL
Intervention: Cerebral PMMRI
Number of subjects: 400
Study: 26051481

Group type: EXPERIMENTAL
Intervention: Enzyme Replacement Therapy (ERT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: N370S/84GG genotype patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Splenectomised patients
Number of subjects: 100
Study: 26053233

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surfactant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both CPAP and Surfactant
Number of subjects: 0
Study: 26053349

Group type: EXPERIMENTAL
Intervention: Person-oriented approach to measuring parenting style
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Socioeconomic status (income)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenting style
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interaction between income and parenting style
Number of subjects: 0
Study: 26053664

Group type: EXPERIMENTAL
Intervention: TN-depleted PBSC grafts
Number of subjects: 35
Study: 26053994

Group type: EXPERIMENTAL
Intervention: General anaesthetic agents (halogenated agents or propofol)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 362
Study: 26054585

Group type: EXPERIMENTAL
Intervention: PDACs (PDA-002)
Number of subjects: 0
Study: 26055218

Group type: EXPERIMENTAL
Intervention: Gla-300
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gla-100
Number of subjects: 20
Study: 26055298

Group type: EXPERIMENTAL
Intervention: Bortezomib plus standard tacrolimus/methotrexate after busulfan/fludarabine MAC
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bortezomib-based MAC HSCT
Number of subjects: 34
Study: 26055439

Group type: EXPERIMENTAL
Intervention: 2nd-graft-arterial group
Number of subjects: 1419
Study: 26056248

Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR) in patients with CKD
Number of subjects: 8400

Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR) in patients without CKD
Number of subjects: 8400

Group type: EXPERIMENTAL
Intervention: Patients with CKD without HPR
Number of subjects: 8400

Group type: EXPERIMENTAL
Intervention: Patients without CKD and without HPR
Number of subjects: 8400
Study: 26056491

Group type: EXPERIMENTAL
Intervention: EE/drospirenone 24/4 regimen
Number of subjects: 594

Group type: COMPARATOR
Intervention: EE/DSG 21/7 regimen
Number of subjects: 594
Study: 26056530

Group type: EXPERIMENTAL
Intervention: Intra-abdominal hypertension (IAH) defined as IAP ≥ 12 mmHg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Duration of intra-abdominal hypertension (IAH)
Number of subjects: 46
Study: 26058673

Group type: EXPERIMENTAL
Intervention: Peripheral artery disease (PAD) group with abnormal ABI (≤ 0.9)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group with normal ABI (> 0.9)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: PAD group
Number of subjects: 124
Study: 26058927

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem cells (MSCs) injection
Number of subjects: 17